NYSE · CIK 0000818686
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Insider trading from SEC Form 4. Last filing 20 d ago. Close $41.10 on Oct 9, 2026, +117% from the 52-week low and 0% from the high.
Last 90 days
Net insider value
-$15M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$15M by 2 insiders
Insiders on file
21
with a Form 4 at this company
Price and insider trades, last year
TEVAOct 9, 2026 · close 41.10
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TEVA PHARMACEUTICAL INDUSTRIES LTD, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | Roberto Mignone director sell | $14M 367,600 shares | -100% | +113% from low-1% from high | |
| 32Weak | Brian Savage Interim Chief Legal Officer sell | $285k 7,342 shares | -46% | +113% from low-1% from high | |
| 39Weak | Eliyahu Sharon Kalif EVP, Chief Financial Officer sell | $952k 55,775 shares | -12% | +38% from low-22% from high | |
| 28Weak | Matthew Shields EVP, Global Operations sell | $106k 6,206 shares | -38% | +34% from low-25% from high | |
| 60Notable | Mark Sabag See "Remarks" sell | $6.1M 337,915 shares | -69% | +41% from low-21% from high | |
| 40Moderate | Richard Daniell Exec. VP, European Commercial sell | $1.1M 70,961 shares | -59% | - | |
| 40Moderate | Richard Daniell Exec. VP, European Commercial sell | $2.2M 140,372 shares | -419% | - | |
| 5Weak | Christine Fox EVP, Head of U.S. Commercial sell | $98k 6,181 shares | -10% | - | |
| 21Weak | Richard D Francis President and CEO sell | $376k 23,773 shares | -8% | - | |
| 30Weak | Eric A Hughes See "Remarks" sell | $367k 23,251 shares | -100% | - | |
| 40Moderate | Richard Daniell Exec. VP, European Commercial sell | $999k 62,250 shares | -100% | - | |
| 28Weak | Richard D Francis President and CEO sell | $503k 31,342 shares | -11% | - | |
| 31Weak | Eric A Hughes See "Remarks" sell | $400k 24,900 shares | -100% | - | |
| 36Weak | Eliyahu Sharon Kalif EVP, Chief Financial Officer sell | $903k 55,750 shares | -27% | - | |
| 40Moderate | Richard D Francis President and CEO sell | $1.3M 75,506 shares | -26% | - | |
| 50Moderate | Roberto Mignone director sell | $6.3M 286,000 shares | -29% | - | |
| 5Weak | Christine Fox EVP, Head of U.S. Commercial sell | $327k 19,388 shares | -31% | - |
Congressional trades
1 trade in TEVA disclosed by members of Congress under the STOCK Act. All congressional trades.
- Alan ArmstrongSenate · R-OK · last Jul 21, 20261 bought
0 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Alan Armstrong Senate · R-OK | Purchase | TEVA Teva Pharmaceutical Industries Limited American Depositary Shares | $1,001 to $15k | Mar 30 / Jul 21 113 days after the trade | eFD |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | MOption exercise Ordinary Shares | +4,503 | $34.70 | $156k | 15,842 | 20 d ago |
| Sep 18, 2026 | Roberto Mignone director | SOpen-market sale Ordinary Sharesindirect: [see footnote] | -367,600 | $39.06 | $14M | 0 | 20 d ago |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | SOpen-market sale Ordinary Shares | -4,503 | $38.69 | $174k | 11,339 | 20 d ago |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | SOpen-market sale Ordinary Shares | -2,525 | $39.15 | $99k | 8,814 | 20 d ago |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | SOpen-market sale Ordinary Shares | -314 | $38.70 | $12k | 8,500 | 20 d ago |
| Sep 18, 2026 | Brian Savage Interim Chief Legal Officer | MOption exercise Stock Options (right to buy)derivative | -4,503 | $34.70 | $156k | 0 | 20 d ago |
| Jun 12, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -55,775 | $17.08 | $952k | 403,288 | Jun 16, 2025 |
| Jun 6, 2025 | Varda Shalev director | MOption exercise Ordinary Shares | +9,632 | - | - | 22,504 | Jun 9, 2025 |
| Jun 5, 2025 | Richard D Francis President and CEO | AGrant or award Restricted Share Unitsderivative | +52,173 | $0.00 | $0 | 52,173 | Jun 9, 2025 |
| Jun 5, 2025 | Chen Lichtenstein director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 6, 2025 | Ronit Satchi-Fainaro director | MOption exercise Ordinary Shares | +9,632 | - | - | 97,909 | Jun 9, 2025 |
| Jun 6, 2025 | Roberto Mignone director | MOption exercise Ordinary Shares | +9,632 | - | - | 105,315 | Jun 9, 2025 |
| Jun 6, 2025 | Rosemary A Crane director | MOption exercise Ordinary Shares | +9,632 | - | - | 113,247 | Jun 9, 2025 |
| Jun 6, 2025 | Sol J Barer director | MOption exercise Ordinary Shares | +17,158 | - | - | 426,272 | Jun 9, 2025 |
| Jun 6, 2025 | Tal Zvi Zaks director | MOption exercise Ordinary Shares | +9,632 | - | - | 58,772 | Jun 9, 2025 |
| Jun 6, 2025 | Janet S. Vergis director | MOption exercise Ordinary Shares | +9,632 | - | - | 73,697 | Jun 9, 2025 |
| Jun 6, 2025 | Gerald M Lieberman director | MOption exercise Ordinary Shares | +9,632 | - | - | 115,657 | Jun 9, 2025 |
| Jun 6, 2025 | Amir Elstein director | MOption exercise Ordinary Shares | +9,632 | - | - | 2,103,963 | Jun 9, 2025 |
| Jun 6, 2025 | Perry Nisen director | MOption exercise Ordinary Shares | +9,632 | - | - | 105,315 | Jun 9, 2025 |
| Jun 6, 2025 | Perry Nisen director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Sol J Barer director | MOption exercise Restricted Share Unitsderivative | -17,158 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Varda Shalev director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Rosemary A Crane director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Tal Zvi Zaks director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Ronit Satchi-Fainaro director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Janet S. Vergis director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Amir Elstein director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Gerald M Lieberman director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 5, 2025 | Gerald M Lieberman director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Amir Elstein director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Perry Nisen director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Ronit Satchi-Fainaro director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Varda Shalev director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Tal Zvi Zaks director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 6, 2025 | Roberto Mignone director | MOption exercise Restricted Share Unitsderivative | -9,632 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 5, 2025 | Janet S. Vergis director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Sol J Barer director | AGrant or award Restricted Share Unitsderivative | +21,739 | $0.00 | $0 | 21,739 | Jun 9, 2025 |
| Jun 5, 2025 | Rosemary A Crane director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 5, 2025 | Roberto Mignone director | AGrant or award Restricted Share Unitsderivative | +14,492 | $0.00 | $0 | 14,492 | Jun 9, 2025 |
| Jun 3, 2025 | Matthew Shields EVP, Global Operations | MOption exercise Ordinary Shares | +16,195 | - | - | 16,195 | Jun 5, 2025 |
| Jun 3, 2025 | Matthew Shields EVP, Global Operations | SOpen-market sale Ordinary Shares | -6,206 | $17.02 | $106k | 9,989 | Jun 5, 2025 |
| Jun 3, 2025 | Matthew Shields EVP, Global Operations | MOption exercise Restricted Share Unitsderivative | -16,195 | $0.00 | $0 | 48,587 | Jun 5, 2025 |
| May 14, 2025 | Evan Lippman EVP, Business Development | AGrant or award Restricted Share Unitsderivative | +47,365 | $0.00 | $0 | 47,365 | May 19, 2025 |
| May 14, 2025 | Evan Lippman EVP, Business Development | AGrant or award Restricted Share Unitsderivative | +148,016 | $0.00 | $0 | 148,016 | May 19, 2025 |
| May 8, 2025 | Mark Sabag See "Remarks" | SOpen-market sale Ordinary Shares | -337,915 | $18.04 | $6.1M | 150,996 | May 12, 2025 |
| Mar 5, 2025 | Placid Jover See "Remarks" | AGrant or award Restricted Share Unitsderivative | +56,603 | $0.00 | $0 | 56,603 | Mar 7, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Ordinary Shares10b5-1 | +22,576 | - | - | 119,345 | Mar 7, 2025 |
| Mar 5, 2025 | Christine Fox EVP, Head of U.S. Commercial | AGrant or award Restricted Share Unitsderivative | +71,278 | $0.00 | $0 | 71,278 | Mar 7, 2025 |
| Mar 5, 2025 | Richard D Francis President and CEO | AGrant or award Restricted Share Unitsderivative | +169,811 | $0.00 | $0 | 169,811 | Mar 7, 2025 |
| Mar 5, 2025 | Eric A Hughes See "Remarks" | AGrant or award Restricted Share Unitsderivative | +78,616 | $0.00 | $0 | 78,616 | Mar 7, 2025 |
| Mar 5, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Ordinary Shares | +21,390 | - | - | 459,063 | Mar 7, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -22,576 | $15.91 | $359k | 96,769 | Mar 7, 2025 |
| Mar 5, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Restricted Share Unitsderivative | -21,390 | $0.00 | $0 | 0 | Mar 7, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -48,385 | $15.90 | $769k | 48,384 | Mar 7, 2025 |
| Mar 5, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | AGrant or award Restricted Share Unitsderivative | +79,664 | $0.00 | $0 | 79,664 | Mar 7, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -22,576 | $0.00 | $0 | 0 | Mar 7, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | AGrant or award Restricted Share Unitsderivative10b5-1 | +69,182 | $0.00 | $0 | 69,182 | Mar 7, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Ordinary Shares10b5-1 | +33,512 | - | - | 33,512 | Mar 6, 2025 |
| Mar 4, 2025 | Christine Fox EVP, Head of U.S. Commercial | MOption exercise Ordinary Shares10b5-1 | +20,461 | - | - | 64,565 | Mar 6, 2025 |
| Mar 4, 2025 | Richard D Francis President and CEO | MOption exercise Ordinary Shares10b5-1 | +50,223 | - | - | 295,556 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Ordinary Shares | +33,512 | - | - | 231,253 | Mar 6, 2025 |
| Mar 4, 2025 | Eric A Hughes See "Remarks" | MOption exercise Ordinary Shares10b5-1 | +23,251 | - | - | 23,251 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -21,870 | $15.73 | $344k | 11,641 | Mar 6, 2025 |
| Mar 4, 2025 | Christine Fox EVP, Head of U.S. Commercial | SOpen-market sale Ordinary Shares10b5-1 | -4,034 | $15.73 | $63k | 60,531 | Mar 6, 2025 |
| Mar 4, 2025 | Richard D Francis President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -15,514 | $15.73 | $244k | 280,042 | Mar 6, 2025 |
| Mar 4, 2025 | Eric A Hughes See "Remarks" | SOpen-market sale Ordinary Shares10b5-1 | -15,174 | $15.73 | $239k | 8,077 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Ordinary Shares | +23,251 | - | - | 254,504 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Ordinary Shares | +183,169 | - | - | 437,673 | Mar 6, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -11,641 | $15.91 | $185k | 0 | Mar 6, 2025 |
| Mar 5, 2025 | Christine Fox EVP, Head of U.S. Commercial | SOpen-market sale Ordinary Shares10b5-1 | -2,147 | $15.91 | $34k | 58,384 | Mar 6, 2025 |
| Mar 5, 2025 | Richard D Francis President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -8,259 | $15.91 | $131k | 271,783 | Mar 6, 2025 |
| Mar 5, 2025 | Eric A Hughes See "Remarks" | SOpen-market sale Ordinary Shares10b5-1 | -8,077 | $15.91 | $129k | 0 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Ordinary Shares10b5-1 | +20,461 | - | - | 20,461 | Mar 6, 2025 |
| Mar 4, 2025 | Christine Fox EVP, Head of U.S. Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -20,461 | $0.00 | $0 | 61,384 | Mar 6, 2025 |
| Mar 4, 2025 | Richard D Francis President and CEO | MOption exercise Restricted Share Unitsderivative10b5-1 | -50,223 | $0.00 | $0 | 150,669 | Mar 6, 2025 |
| Mar 4, 2025 | Eric A Hughes See "Remarks" | MOption exercise Restricted Share Unitsderivative10b5-1 | -23,251 | $0.00 | $0 | 69,754 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Restricted Share Unitsderivative | -33,512 | $0.00 | $0 | 33,512 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -13,353 | $15.73 | $210k | 7,108 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Restricted Share Unitsderivative | -23,251 | $0.00 | $0 | 69,754 | Mar 6, 2025 |
| Mar 4, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | MOption exercise Restricted Share Unitsderivative | -183,169 | $0.00 | $0 | 0 | Mar 6, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -7,108 | $15.91 | $113k | 0 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Ordinary Shares10b5-1 | +183,169 | - | - | 183,169 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -56,385 | $15.73 | $887k | 126,784 | Mar 6, 2025 |
| Mar 5, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -30,015 | $15.91 | $478k | 96,769 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -33,512 | $0.00 | $0 | 33,512 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -20,461 | $0.00 | $0 | 61,384 | Mar 6, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -183,169 | $0.00 | $0 | 0 | Mar 6, 2025 |
| Mar 3, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Ordinary Shares10b5-1 | +62,250 | - | - | 62,250 | Mar 5, 2025 |
| Mar 3, 2025 | Richard D Francis President and CEO | MOption exercise Ordinary Shares10b5-1 | +67,231 | - | - | 276,675 | Mar 5, 2025 |
| Mar 3, 2025 | Eric A Hughes See "Remarks" | MOption exercise Ordinary Shares10b5-1 | +24,900 | - | - | 24,900 | Mar 5, 2025 |
| Mar 3, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -49,314 | $16.19 | $798k | 12,936 | Mar 5, 2025 |
| Mar 3, 2025 | Richard D Francis President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -24,892 | $16.19 | $403k | 251,783 | Mar 5, 2025 |
| Mar 3, 2025 | Eric A Hughes See "Remarks" | SOpen-market sale Ordinary Shares10b5-1 | -19,726 | $16.19 | $319k | 5,174 | Mar 5, 2025 |
| Mar 4, 2025 | Richard Daniell Exec. VP, European Commercial | SOpen-market sale Ordinary Shares10b5-1 | -12,936 | $15.56 | $201k | 0 | Mar 5, 2025 |
| Mar 4, 2025 | Richard D Francis President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -6,450 | $15.56 | $100k | 245,333 | Mar 5, 2025 |
| Mar 4, 2025 | Eric A Hughes See "Remarks" | SOpen-market sale Ordinary Shares10b5-1 | -5,174 | $15.56 | $80k | 0 | Mar 5, 2025 |
| Mar 3, 2025 | Richard Daniell Exec. VP, European Commercial | MOption exercise Restricted Share Unitsderivative10b5-1 | -62,250 | $0.00 | $0 | 124,503 | Mar 5, 2025 |
| Mar 3, 2025 | Richard D Francis President and CEO | MOption exercise Restricted Share Unitsderivative10b5-1 | -67,231 | $0.00 | $0 | 134,462 | Mar 5, 2025 |
| Mar 3, 2025 | Eric A Hughes See "Remarks" | MOption exercise Restricted Share Unitsderivative10b5-1 | -24,900 | $0.00 | $0 | 49,801 | Mar 5, 2025 |
| Feb 28, 2025 | Eliyahu Sharon Kalif EVP, Chief Financial Officer | SOpen-market sale Ordinary Shares10b5-1 | -55,750 | $16.21 | $903k | 147,941 | Mar 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Sol J Barerdirector
- Rosemary A Cranedirector
- Richard DaniellExec. VP, European Commercial
- Amir Elsteindirector
- Christine FoxEVP, Head of U.S. Commercial
- Richard D FrancisPresident and CEO
- Eric A HughesSee "Remarks"
- Placid JoverSee "Remarks"
- Eliyahu Sharon KalifEVP, Chief Financial Officer
- Gerald M Liebermandirector
- Chen Lichtensteindirector
- Evan LippmanEVP, Business Development
- Roberto Mignonedirector
- Perry Nisendirector
- Mark SabagSee "Remarks"
- Ronit Satchi-Fainarodirector
- Brian SavageInterim Chief Legal Officer
- Varda Shalevdirector
- Matthew ShieldsEVP, Global Operations
- Janet S. Vergisdirector
- Tal Zvi Zaksdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.